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Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition due to the asso-
ciation of an infectious agent with lymphocyte cytotoxicity defects, either of congenital
genetic origin in children or presumably acquired in adults. In HLH patients, an excess
of lymphocyte or macrophage cytokines, such as IFN-γ and TNFα is present in serum. In
animal models of the disease, IFN-γ and TNF-α have been shown to play a central path-
ogenic role. In humans, unusually high concentrations of IL-18, an inducer of IFN-γ, and
TNF-α have been reported, and are associated with an imbalance between IL-18 and its
natural inhibitor IL-18 binding protein (IL-18BP) resulting in an excess of free IL-18. Here we
studied whether IL-18BP could reduce disease severity in an animal model of HLH. Mouse
cytomegalovirus infection in perforin-1 knock-out mice induced a lethal condition similar to
human HLH characterized by cytopenia with marked inflammatory lesions in the liver and
spleen as well as the presence of hemophagocytosis in bone marrow. IL-18BP treatment
decreased hemophagocytosis and reversed liver as well as spleen damage. IL-18BP treat-
ment also reduced both IFN-γ andTNF-α production by CD8+ T and NK cells, as well as Fas
ligand expression on NK cell surface. These data suggest that IL-18BP is beneficial in an
animal model of HLH and in combination with anti-infectious therapy may be a promising
strategy to treat HLH patients.
Keywords: IL-18, IL-18 binding protein, natural killer cells, hemophagocytic lymphohistiocytosis, macrophage
activation syndrome
INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening
syndrome affecting children and adults, characterized by persis-
tent fever, hepato-splenomegaly, cytopenia, hypertriglyceridemia,
hyperferritinemia, and the presence of hemophagocytosis in bone
marrow or other tissues (Henter et al., 2007; Janka, 2007). The dis-
ease can be of genetic origin, affecting children before 6 months
of age, secondary to various mutations affecting genes coding
for proteins involved in lymphocyte cytotoxicity, the prototypic
form being perforin deficiency in familial HLH (F-HLH) type 2
(Stepp et al., 1999; Henter et al., 2007; Janka, 2007). Other muta-
tions have been reported to be associated with F-HLH, such as
mutations affecting Munc 13-4 in F-HLH type 3, syntaxin 11 in
F-HLH type 4, Munc 18-2 in F-HLH type 5, as well as muta-
tions of Rab27a in Griscelli syndrome and Lyst in Chediak–Higashi
syndrome (Pachlopnik Schmid et al., 2010). In this genetic con-
text of severely impaired lymphocyte cytotoxicity, infection often
appears to be a necessary trigger to induce the disease (Henter
et al., 2007; Pachlopnik Schmid et al., 2010).
In adults, HLH is encountered in association with a variety of
underlying conditions notably viral infections due to herpes virus
family members such as Epstein–Barr virus (EBV), herpes simplex,
and cytomegalovirus (CMV; Henter et al., 2007; Rouphael et al.,
2007). Other intracellular infections, hematological malignancies
notably T cell lymphoma but also auto-immune diseases such
as systemic lupus erythematosus and particularly inflammatory
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diseases such as systemic onset juvenile idiopathic arthritis (also
known as Still’s disease) are also associated with secondary HLH
(S-HLH; Ravelli, 2002; Lambotte et al., 2006). In adult patients,
lymphocyte cytotoxicity is also frequently compromised due to
previous immunosuppressive treatments or to unknown mecha-
nisms (Grom, 2004; Mazodier et al., 2005). In addition, some adult
patients affected by S-HLH carry mutations of genes involved in
F-HLH, such as perforin and Munc 13-4, although in less severe
forms than those observed in F-HLH (Clementi et al., 2002; Zhang
et al., 2008). These observations have led to the concept that
the combination of an infectious trigger with severely impaired
lymphocyte cytotoxicity is required to induce HLH in patients
(Pachlopnik Schmid et al., 2010). Another characteristic of this
disease is the large excess of cytokines secreted by lymphocytes
(IFN-γ, sIL-2R) and macrophages (TNF-α, GM-CSF) which is
commonly observed in these patients and may be responsible for
most of the clinical and biological symptoms (Henter et al., 1991).
Progress in the pathogenesis of HLH has been obtained in ani-
mal models. Several models have been reported to date, they each
combine mutations affecting lymphocyte cytotoxicity plus a viral
infection (Kägi et al., 1994; Walsh et al., 1994; Jordan et al., 2004;
Van Dommelen et al., 2006; Crozat et al., 2007; Pachlopnik Schmid
et al., 2008). The more suitable model appears to be lympho-
cytic choriomeningitis (LCMV) infection in perforin-1 knock-out
mice (Perf1 KO; Kägi et al., 1994; Walsh et al., 1994; Jordan et al.,
2004). In this model, IFN-γ but not other cytokine blockade, can
increase survival therefore identifying IFN-γ as a major cytokine
in HLH pathogenesis (Jordan et al., 2004). While LCMV is a non-
cytopathic virus (Kägi et al., 1994), HLH in humans is commonly
associated with severe sepsis or cytopathic viral infections, such as
CMV, fatal H5N1, or H1N1 influenza A viruses (Janka et al., 1998;
Yuen et al., 1998; Riedemann et al., 2003; Rouphael et al., 2007).
Another murine model has been described consisting in mouse
CMV (MCMV) infection in Perf1 KO mice (Van Dommelen et al.,
2006). In that model, both IFN-γ and TNF-α appear to be required
for tissue damage (Van Dommelen et al., 2006).
IL-18 is a member of the IL-1 family produced by macrophages,
peripheral blood mononuclear cells (PBMCs), or dendritic cells as
a 24 kDa precursor inactive form which is cleaved by caspase-1
in a 18 kDa mature biologically active molecule (Dinarello and
Kaplanski, 2005; Dinarello, 2007). IL-18 induces IFN-γ produc-
tion by NK cells and T cells in combination with IL-12 (Dinarello,
2007). IL-18 is also able to induce TNF-α and chemokine secretion
by macrophages (Dinarello, 2007). IL-18 binding protein (IL-
18BP) is the natural inhibitor of IL-18 in vivo, and is a potent
inhibitor of IFN-γ production (Novick et al., 1999). Various stud-
ies have reported that circulating levels of IL-18 are high in patients
with both forms of HLH and its levels correlate with the various
HLH markers (Takada et al., 1999; Dinarello and Kaplanski, 2005;
Mazodier et al., 2005). In addition, we have reported an imbal-
ance of IL-18BP/IL-18 in S-HLH patients leading to an excess of
free IL-18, which likely contributes to the large excess of IFN-
γ and TNF-α found in these patients (Mazodier et al., 2005).
Recombinant human IL-18BP inhibits IL-18 with a Kd in the
nanomolar range (Novick et al., 1999), an affinity far greater than
the naturally occurring cell receptor. In addition, IL-18BP neu-
tralizes IL-18 at concentrations significantly lower than soluble
forms (extracellular domain) of the IL-18 receptor alpha chain
(Reznikov et al., 2002). Recombinant human IL-18BP has been
shown to be as potent as the natural IL-18BP and to be safe in
preliminary human trials conducted in psoriasis or rheumatoid
arthritis (Dinarello and Kaplanski, 2005; Tak et al., 2006; Dinarello,
2007). We took advantage of the absence of species specificity of
IL-18BP and tested it in a model of MCMV-infected Perf1 KO mice
to determine whether IL-18 could be a target for the treatment of
HLH in humans.
RESULTS
PERFORIN-DEFICIENT MICE INFECTED WITH MCMV: AN ANIMAL
MODEL OF HLH
We examined perforin-deficient mice infected with MCMV to
determine whether they could represent a model of HLH. These
mice do not spontaneously develop any syndrome, but they
are unable to control MCMV infection (Orange and Biron,
1996). When inoculated with 1.5× 104 PFU of MCMV, BL/6
WT mice normally survived infection, showing no sign of ill-
ness, however Prf1 KO mice died between day 6 and day 13
after infection (Figure 1A). Starting from day 3, mice developed
severe illness, manifested by progressive cachexia, weight loss, and
splenomegaly (data not shown). At day 6 after infection, Prf1 KO
mice were pancytopenic affecting leukocytes, lymphocytes, and
platelets (Figure 1B). Moreover, the analysis of the bone marrow
revealed the presence of activated macrophages with evidence of
hemophagocytosis affecting platelets (P), lymphocytes (L), and
neutrophils (N; Figure 1C). Thus, Perf1 KO mice infected with
MCMV develop a clinical and hematological picture similar to
that observed in humans with HLH.
BLOCKING IL-18 ABROGATES HISTOLOGICAL LESIONS IN
MCMV-ASSOCIATED HLH
We blocked IL-18 using IL-18BP administration in order to test
whether this treatment can improve the illness. Prf1 KO and BL/6
WT control mice were infected with MCMV and treated with
10µg of IL-18BP or vehicle starting 84 h after infection. We chose
to block IL-18 at day 3.5 after infection to avoid affecting endoge-
nous antiviral effects, such as the induction of IFN-γ production
that contributes to the early control of MCMV infection (Orange
and Biron, 1996). IL-18BP administration did not show any effect
on mice survival, neither for Prf1 KO mice (Figure 2A) nor for
BL/6 WT mice, whose normal resistance to MCMV infection was
not altered (not shown). Prf1 KO mice succumbed to MCMV
infection with high viral replication; indeed, plaque assay of liver
homogenates showed viral titers >1000-fold higher in Prf1 KO
mice than in WT mice at day 6 after inoculation (Figure 2B), a
time when Prf1 KO mice were in the exacerbation phase of the
disease and before they began to die. IL-18BP thus did not affect
viral replication in Prf1 KO mice nor in BL/6 WT mice (Figure 2B).
In order to assess the extent of spleen and liver damage in
BL/6 WT and Prf1 KO mice after MCMV infection and the
possible effect of IL-18BP, we defined a semi-quantitative histo-
logical score ranging from normal histology (grade 0) to severe
lesions (grade 3; Figure 2C). Six days after MCMV infection,
Prf1 KO mice were affected by multiple histologic changes con-
sistent with hemophagocytic syndrome (Figure 2D). Liver and
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FIGURE 1 | Prf1 KO mice infected with mouse CMV (MCMV)
display increased mortality compared to BL/6 WT mice and
develop an HLH-like phenotype. (A) Kaplan–Meier survival curves:
BL/6 WT mice and Prf1 KO mice were infected with 1.5×104 PFU of
MCMV WT and survival was monitored for 15 days after infection.
N =20 mice per group. (B) White blood cell, lymphocyte, and platelet
counts in peripheral blood of MCMV-infected BL/6 WT and Prf1 KO
mice, 6 days after infection. Cell numbers are expressed as
mean±SEM. N = 4 mice per group. *p<0.05; ***p< 0.001.
(C) Hemophagocytosis in the bone marrow of MCMV-infected Prf1
KO mice: activated macrophages engulfing platelets (P), lymphocytes
(L), neutrophils (N). Magnification ×100.
spleen of Prf1 KO mice were seriously damaged by MCMV infec-
tion, showing grade 3 lesions whereas after IL-18BP treatment,
infected Prf1 KO mice showed grade 1 lesions both in the liver
and the spleen (Figure 2D). BL6/WT and BL6/WT treated with
IL-18BP all showed normal histology (data not shown). Impor-
tantly, hemophagocytosis in bone marrow was also abrogated
by IL-18BP treatment. Together, these data indicated that IL-18
is a non-redundant mediator of organ damage, since treatment
with IL-18BP abrogated histological lesions induced by MCMV in
spleen and liver.
TREATMENT WITH IL-18BP REDUCES IFN-γ AND TNF-α PRODUCTION
In HLH, organ damage is triggered by high levels of proin-
flammatory cytokines, which activate histiocytes and promote
the infiltration of inflammatory cells. Notably, in Prf1 KO mice
developing HLH following MCMV infection, TNF-α and IFN-γ
contribute to the pathogenesis of the disorder, as specific blockade
of either cytokine is protective (Orange and Biron, 1996;Van Dom-
melen et al., 2006). Since IL-18 induces cytokines and chemokines,
up-regulates VCAM–1 in hepatic sinusoidal endothelial cells as
well as stimulates the production of IFN-γ and TNF-α (Dinarello,
2007), we tested whether IL-18BP administration could reduce
the levels of these cytokines. Serum concentrations of IFN-γ and
TNF-α were measured in Prf1 KO and BL/6 WT mice 6 days after
MCMV infection (Figure 3A). The level of both cytokines was
greatly increased in Prf1 KO mice compared to BL/6 WT mice, but
treatment with IL-18BP significantly reduced by half the serum
levels of both IFN-γ and TNF-α (Figure 3A). In order to assess the
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FIGURE 2 | IL-18BP does not improve Prf1 KO mice survival after
mouse CMV (MCMV) infection but consistently reduces inflammatory
lesions in the liver and spleen. (A) Kaplan–Meier survival curves for Prf1
KO mice infected with 1.5×104 PFU of MCMV, treated or not with IL-18BP.
N =20 mice per group. (B) MCMV titers in liver homogenates of BL/6 WT
and Prf1 KO mice, with or without IL-18BP, 6 days after infection. The data
are expressed as mean±SEM. N = 3 mice per group. (C) Histological
score of liver and spleen sections from MCMV‘infected mice, stained with
(Continued)
FIGURE 2 | Continued
hematoxylin and eosin. In the liver, grade 1 lesions were defined as
near-normal histology with only very few small clusters of inflammatory
cells (black arrows); grade 2 lesions were defined as moderate number of
small and non-confluent clusters of inflammatory cells; grade 3 lesions
were defined as numerous, large, and often confluent clusters of
inflammatory cells replacing normal hepatic lobules and portal tracts. In the
spleen, grade 1 lesions showed only a slight accumulation in the red pulp of
mononuclear clear cells (arrow heads) around well preserved islets of white
pulp (black stars); grade 2 lesions were defined as a more prominent
accumulation of mononuclear clear cells around less preserved areas of
white pulp; grade 3 lesions were defined as large amounts of mononuclear
clear cells accumulating in the red pulp around small remnants of white
pulp. (D) Histological lesions in MCMV-infected Prf1 KO mice: IL-18BP
prevents severe histological damage. Histological score is indicated in the
figure. The photomicrographs are representative of three independent
experiments each with three mice per group.
source of IFN-γ, we measured the levels of cytoplasmic IFN-γ by
flow cytometry in liver and spleen cell suspensions from Prf1 KO
mice 6 days after MCMV infection, without any further in vitro
stimulation. Both NK cells and CD8+ T lymphocytes contributed
to IFN-γ production during the late phase of MCMV infection
(Figure 3B). IL-18BP reduced IFN-γ production in CD8+ T cells
as well as in NK cells in the spleen. Interestingly in the liver, IL-
18BP suppressed IFN-γ production by NK cells to a greater degree
than in T cells, reducing levels to those observed in uninfected
mice (Figures 3B,C).
ANTIVIRAL DRUG AND IL-18BP COMBINATION THERAPY BLOCKS THE
MEDIATORS OF ORGAN DAMAGE
In Prf1 KO mice, HLH is triggered by MCMV infection but as
viral replication increases rapidly, the infection becomes lethal. In
an attempt to mimic the treatment option in humans by combin-
ing anti-infectious drugs with an immunomodulatory agent, we
used a genetically engineered MCMV strain, DN-SCP-MCMV, for
which in vivo replication can be arrested by the administration
of doxycycline (DOX; Robbins et al., 2007). Prf1 KO mice were
infected with 1× 106 PFU of in vitro-derived DN-SCP-MCMV
and starting 84 h after infection, mice received DOX, IL-18BP,
or a combination of both. All Prf1 KO mice infected with DN-
SCP-MCMV developed a severe illness with profound leukopenia
and thrombocytopenia (Figure A1A in Appendix). As shown in
Figure 4A, treatment with DOX was not sufficient to rescue Prf1
KO mice, as mice succumbed by day 10. Consistent with this obser-
vation, viral burdens in liver homogenates were determined 6 days
after infection by plaque assay and we unfortunately observed that
DOX was not sufficient to totally block viral replication in our
mice (Figure A1B in Appendix). DN-SCP-MCMV-infected mice
treated with IL-18BP alone also succumbed by day 10,but although
it did not reach statistical significance, a slight trend toward a bet-
ter survival up to day 12 was nevertheless observed when the mice
received a combination of DOX and IL-18BP (Figure 4A).
The histological analysis of the liver and spleen of Prf1 KO
mice infected with DN-SCP-MCMV exhibited the same grade 3
lesions than those observed in Prf1 KO mice infected with MCMV
(Figure 4B). Consistent with the lack of complete effects of DOX
on viral replication, Prf1 KO mice infected with DN-SCP-MCMV
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FIGURE 3 | IFN-γ andTNF-α production is reduced upon treatment with
IL-18BP. (A) Serum concentrations of IFN-γ and TNF-α in BL/6 WT and Prf1 KO
mice 6 days after mouse CMV (MCMV) infection were determined by ELISA.
Mean±SEM of three independent experiments, N =5 mice per group.
**p<0.01. (B) Frequency of IFN-γ+ NK cells and CD8+ T lymphocytes from
liver and spleen of Prf1 KO mice 6 days after MCMV infection. Results are
expressed as mean±SEM of four mice per group. *p<0.05; **, p< 0.01;
***p<0.001. (C) Representative flow cytometric analysis of IFN-γ expression
by liver NK cells from vehicle treated Prf1 KO mouse, IL-18BP treated Prf1 KO
mouse, BL/6 WT mouse, 6 days after MCMV infection.
and treated with DOX showed only minimal histological improve-
ment (grade 2), whereas a combination of DOX and IL-18BP
significantly improved histological damages to grade 1 and grade
0 in the liver and spleen, respectively.
In order to characterize the mechanism of action of IL-18BP
in these experimental conditions, we examined changes in IFN-
γ, TNF-α, and Fas ligand (FasL). In order to compare with the
observations obtained in Prf1KO mice infected with WT MCMV,
IFN-γ and TNF-α were quantified by ELISA in the sera of Prf1 KO
mice infected with DN-SCP-MCMV. Similar to the WT MCMV,
the engineered virus DN-SCP-MCMV also induced high levels of
both cytokines (Figure 4C). Treatment with DOX that only par-
tially blocked viral replication (Figure A1B in Appendix), likewise
was not effective in the control of IFN-α and TNF-α levels. On
the contrary, IL-18BP administration significantly reduced serum
concentrations of both cytokines, confirming data observed in Prf1
KO mice infected with WT MCMV. Furthermore, combination of
the antiviral effect of DOX with IL-18BP resulted in the abrogation
of IFN-γ and TNF-α production (Figure 4C). FasL was measured
by flow cytometry on NK cells derived from Prf1KO and BL/6
WT mice livers, 6 days after infection with DN-SCP-MCMV. In
infected Prf1 KO mice, FasL expression was increased compared
to infected WT mice (Figure 4D) and was consistently reduced
by the administration of DOX and more strongly by those of
IL-18BP. Thus, despite the lack of efficacy of DOX treatment to
eliminate DN-SCP-MCMV infection, these experiments confirm
with another viral strain the beneficial role of IL-18BP in treating
the inflammatory syndrome observed in Prf1 KO mice infected
with MCMV.
DISCUSSION
Since the levels of free IL-18 are unusually high and correlate with
disease severity in humans with HLH (Dinarello and Kaplanski,
2005; Mazodier et al., 2005) the present study was conducted to
evaluate the therapeutic potential of neutralizing IL-18 with IL-
18BP in a mouse model of HLH. We subjected Perf1 KO mice
to infection with MCMV, which induces IFN-γ and TNF-α (Van
Dommelen et al., 2006) and observed that these mice indeed
developed a lethal condition similar to HLH, with pancytopenia,
hemophagocytosis in the bone marrow and severe inflammation
in the liver and spleen. We observed that IL-18BP treatment alone
decreased hemophagocytosis and dramatically reversed liver and
spleen damage induced by MCMV infection consistently with
decreased levels of both IFN-γ and TNF-α and reduced expression
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FIGURE 4 | IL-18BP combined with doxycycline (DOX) abrogates
histological lesions and reduces the production of the mediators of
organ damage. (A) Kaplan–Meier survival curves: Prf1 KO mice were
infected with DN-SCP-MCMV and treated with IL-18BP, doxycycline, or both.
Survival was monitored for 15 days post-infection. N =5 mice per group.
(B) Histological analysis of liver and spleen from Prf1 KO mice infected with
DN-SCP-MCMV: hematoxylin and eosin stained sections, representative of
three mice per group. Histological score is indicated in the figure. (C) IFN-γ
and TNF-α serum concentrations from Prf1 KO mice 6 days after infection with
DN-SCP-MCMV and treated with IL-18BP, DOX, or both. Mean±SEM of three
mice per group. *p<0.05; **p<0.01; ***p<0.001; n.s., not significant.
(D) Fas ligand (FasL) expression in liver NK cells derived from Prf1 KO mice
and BL/6 WT mice 6 days after DN-SCP-MCMV infection and treated with
IL-18BP, doxycycline, or both. Mean±SEM frequency of FasL positive NK
cells in Prf1 KO mice and BL/6 WT mice. N =3 mice per group. *p<0.05;
**p<0.01; ***p<0.001.
of FasL on NK cells. However, and different from LCMV-infected
Perf1 KO mice treated with anti-IFN-γ (Jordan et al., 2004), sur-
vival was not improved in MCMV-infected Perf1 KO mice treated
with IL-18BP. This was not due to a viral burden increase due
to IL-18 and it seems unlikely that higher doses of IL-18BP
would have reduced lethality, since IL-18BP at the present dose
was very effective in reducing both IFN-γ and TNF-α. In this
model, complete control of MCMV replication was not achieved
despite the use of a genetically designed antiviral strategy with
DOX. Since immune defenses against MCMV infection depend
on perforin-mediated mechanisms (Bukowski et al., 1984; Orange
and Biron, 1996; Van Dommelen et al., 2006), persistent infection
with this cytopathic virus was probably responsible for animal
death.
HLH appears to result from an infectious trigger in patients
with compromised lymphocyte cytotoxicity, either due to genetic
mutations in F-HLH or to poorly understood conditions in
S-HLH (Grom, 2004; Mazodier et al., 2005; Henter et al., 2007;
Pachlopnik Schmid et al., 2010). The common paradigm concern-
ing HLH pathogenesis involves a two-step mechanism: first, poly-
clonal CD8+ T cell proliferation takes place due to continuous
infectious stimulation leading to large excess IFN-γ produc-
tion. High levels of IFN-γ induce in a second step, macrophage
activation, with production of inflammatory cytokines and hemo-
phagocytosis (Jordan et al., 2004; Pachlopnik Schmid et al., 2010).
This concept is largely the result of studies performed in LCMV-
infected Perf1 KO mice, the more accepted animal model of HLH
to date (Kägi et al., 1994; Walsh et al., 1994; Jordan et al., 2004).
Indeed it appears from this model that uncontrolled proliferation
of non-cytotoxic CD8+ T cells is the central event leading to excess
IFN-γ production and HLH (Kägi et al., 1994; Walsh et al., 1994;
Jordan et al., 2004). However, LCMV by itself induces profound
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CD8+ T cell proliferation and activation, even in wild-type ani-
mals and immune defenses against this virus have been shown
to rely on IFN-γ produced by CD8+ T cells as well as perforin-
mediated CD8+ T cell cytotoxicity, independently of HLH occur-
rence (Kägi et al., 1994; Badovinac et al., 2003). In LCMV-infected
Perf1 KO mice, NK cells do not appear to be involved in HLH
pathogenesis, but immune defenses against LCMV do not involve
NK cells (Bukowski et al., 1983). In addition, in LCMV-infected
Perf1 KO mice, blocking IFN-γ improves survival, whereas block-
ade of either TNF-α, IL-2, IL-12, or IL-18 was inefficient (Jordan
et al., 2004). This may appear quite surprising since IL-12 and
IL-18 are potent IFN-γ inducers in vivo and are indeed found in
large concentrations in these mice (Jordan et al., 2004). Although
clinically inconsistent, other therapies have reported the beneficial
effects of cyclosporin, anti-TNF-α blocking agents, or anti-CD25
mAb in human HLH (Prahalad et al., 2001; Henter et al., 2007; Olin
et al., 2008). Although conclusions drawn from LCMV-infected
Perf1 KO mice may be relevant to human HLH induced by non-
cytopathic virus such as EBV, it is also a possibility that these
conclusions would be different if infection with another virus was
used.
In humans, S-HLH can complicate more severe situations such
as sepsis or infections due to cytopathic virus, notably CMV or
H5N1 and H1N1 influenza virus (Yuen et al., 1998; Riedemann
et al., 2003; Rouphael et al., 2007; To et al., 2010). The MCMV-
infected Perf1 KO model used in this study may be more relevant
to such situations, since MCMV is a cytopathic virus (Bukowski
et al., 1983, 1984; Van Dommelen et al., 2006). NK cell perforin-
mediated cytotoxicity is essential for the control of MCMV infec-
tion in the liver, thus in Perf1 KO mice, MCMV persists in tissues,
notably the liver, inducing severe tissue damage due to continuous
T and NK cell activation (Van Dommelen et al., 2006). Both IFN-
γ and TNF-α have been shown to be involved in tissue damage
and anti-TNF-α treatment is partly protective (Van Dommelen
et al., 2006). Liver involvement is consistently observed in human
HLH; CD8+ T cells and macrophages/histiocytes are frequently
observed to infiltrate the liver and it is liver failure that signals
a severe prognosis of the disease (Chen et al., 2010). In other
disease models involving the liver, IL-18 plays an important role
through different mechanisms (Tsutsui et al., 2000). For exam-
ple, IL-18 acts in synergy with IL-12 for IFN-γ production by
hepatic T lymphocytes which in turn induces TNF-α secretion by
Kupffer cells (Tsutsui et al., 2000). IL-18 by itself or in synergy
with IL-2 is also a potent inducer of NK cell cytotoxicity through
activation of the perforin and FasL pathways (Dao et al., 1998;
Tsutsui et al., 2000). In IL-18 transgenic mice, hepatic lesions are
entirely mediated by NK and FasL/Fas mechanisms and hepato-
cytes spontaneously express Fas (Finotto et al., 2004). Similarly,
in various murine models, IL-18 in combination with IL-12 or
IL-2 exerts its anti-tumoral effects through activation of NK cells
and FasL pathways (Osaki et al., 1998; Wigginton et al., 2002). In
the present study, we observed that both liver-infiltrating CD8+
T cells and NK cells are indeed strong producers of IFN-γ and
TNF-α and that these two cytokines could be largely reduced by IL-
18BP treatment. In addition, we observed that expression of FasL
was markedly increased on NK cells in the liver but nearly com-
pletely prevented by IL-18BP treatment. From these studies the
concept emerges that FasL is likely causative in HLH tissue lesions,
in agreement with previous reports showing that high levels of sol-
uble FasL circulate in humans with HLH (Hasegawa et al., 1998).
Since IFN-γ induces Fas expression on cell membranes (Tsutsui
et al., 2000), inhibition of IFN-γ production by IL-18BP can also
decreased Fas expression on target cells and IL-18BP may thus
completely inhibit this cell death mechanism. Moreover, the ability
of FasL/Fas to induce IL-18 takes place independent of caspase-1
(Tsutsui et al., 1999). Thus, beside its protective property reducing
liver or spleen cell death, inhibition of FasL-Fas interactions by IL-
18BP may defeat an amplification loop of IL-18 secretion, which
can be locally deleterious.
S-HLH treatment in humans relies on different strategies such
as anti-infectious agents combined with steroids or cyclosporin
(Ravelli, 2002; Henter et al., 2007; Janka, 2007). In refractory
cases, etoposide is frequently used and in F-HLH, the Interna-
tional Histiocyte Society guidelines recommend the combined use
of steroids, etoposide, cyclosporin and intrathecal methotrexate
before bone marrow transplantation in case of recurrence (Hen-
ter et al., 2007). This treatment regimen, although effective, is not
without serious side effects and a case of acute leukemia occurring
in a patient previously treated for EBV-associated HLH has been
recently reported (Sathiyamoorthy et al., 2011). Because of its pos-
sible side effects, etoposide is not commonly used in patients with
S-HLH, for example, in patients with auto-immune or inflamma-
tory diseases. There is clearly a need for new treatments. In this
context, anti-TNF-α agents, anti-CD25, or IL-1 receptor antago-
nist have been used with varying degrees of success (Prahalad et al.,
2001; Behrens et al., 2006; Olin et al., 2008). In view of the data
obtained in animal models of HLH using LCMV infection, iden-
tifying IFN-γ as a major pathogenic player in HLH pathogenesis,
it has been suggested to use an anti-IFN-γ therapy (Pachlopnik
Schmid et al., 2009, 2010).
Targeting IL-18 with IL-18BP is thus a rationale mechanism
to reduce IFN-γ in HLH since we have observed that IL-18BP
concentrations are inadequately elevated in S-HLH patients in
comparison with increased IL-18, leading to large excess of free IL-
18 which induces IFN-γ (Dinarello and Kaplanski, 2005; Mazodier
et al., 2005). The IL-18BP promoter contains an IFN-γ-responsive
element and IFN-γ is an effective inducer of IL-18BP production
(Paulukat et al., 2001; Hurgin et al., 2002). A failure in the abil-
ity of IFN-γ to induce IL-18BP may explain the IL-18/IL-18BP
imbalance observed in HLH. In agreement with this hypothesis,
a report has shown that in a FHL-type 2 patient, in vitro IFN-γ-
induction of IL-18BP was markedly reduced (Nold-Petry et al.,
2010). These observations in humans together with the benefit of
IL-18BP protection against tissue damage in an animal model of
HLH may support the use of IL-18BP in humans afflicted with this
disease. Therefore, the use of effective antiviral drugs to decrease
viral replication combined with IL-18BP to control organ dam-
age induced by the overwhelming inflammatory reaction may be
a particularly attractive therapeutic option for humans with HLH.
MATERIAL AND METHODS
MICE, VIRUSES, AND IN VIVO TREATMENTS
C57BL/6 mice were purchased from Charles River Laboratories
(L’Arbesle, France). Prf1 KO mice on C57BL/6 background were
www.frontiersin.org August 2012 | Volume 3 | Article 239 | 7
Chiossone et al. IL-18 binding protein in hemophagocytic lymphohistiocytosis
obtained from Jackson Laboratory (Bar Harbor, ME). All mice
were used between 6 and 14 weeks of age. All experiments have
been performed in accordance with protocols approved by the
local ethical committee. MCMV infections were established on
day 0 by i.p. injection of 1.5× 104 PFU of salivary gland propa-
gated MCMV of Smith strain WT (Henter et al., 2007) or 1× 106
PFU of in vitro-derived DN-SCP-MCMV (Janka, 2007). These
modest doses were chosen because they do not induce mortal-
ity in BL/6 WT mice. IL-18BP treatment consisted of daily i.p.
injections of 10µg per mouse of recombinant human IL-18BP
(a generous gift from Merck Serono, Geneva, Switzerland), start-
ing 84 h after infection. Vehicle was saline. For the in vivo arrest
of DN-SCP-MCMV replication, 200µg DOX (Sigma) was deliv-
ered by i.p. injection 84 h after infection followed by the addition
of 2 mg/ml DOX plus 5% sucrose in drinking water. In survival
experiments, mice were infected and assessed for mortality at least
once daily for 15 days.
SERUM CYTOKINES DETECTION AND COMPLETE BLOOD COUNTS
Six days after MCMV infection mice were bled from the retro-
orbital plexus and the concentrations of IFN-γ and TNF-α in
the serum were assayed by ELISA (R&D Systems, Minneapo-
lis, MN, USA). For complete blood cell counts, blood samples
were run a blood cell counter ABX Pentra 60 C+ Horiba Medical
(Montpellier, France).
HISTOLOGY AND ANALYSIS OF HEMOPHAGOCYTOSIS
Six days after MCMV infection, mice were sacrificed and the
spleens and livers removed. Organs were fixed in 10% buffered
formalin in saline, embedded in paraffin, sectioned, stained with
hematoxylin,and counterstained with eosin. Cell suspensions were
prepared from bone marrow and analyzed for the presence of
hemophagocytosis after staining with May-Grünwald-Giemsa.
VIRAL TITER QUANTIFICATION
Six days after MCMV infection mice were sacrificed and liv-
ers were collected, weighted, and homogenized. Viral titers were
determined by a standard plaque assay using NIH-3T3 cells.
FLOW CYTOMETRY AND INTRACELLULAR IFN-γ QUANTIFICATION
Lymphocyte suspensions were prepared from livers and spleens
as described previously (Walzer et al., 2007) and then incubated
for 4 h in the presence of GolgiStop (BD Biosciences, San Jose,
USA). Cells were then harvested and incubated with the following
monoclonal antibodies against cell surface antigens: PerCP anti-
NK1.1, APC anti-mouse TCRβ, Pacific Blue anti-mouse CD4 and
APC-H7 anti-mouse CD8 from BD Pharmingen (San Diego, CA,
USA); PE anti-mouse CD178 (Fas Ligand) from e-Bioscience (San
Diego, CA, USA). For intracellular staining, samples were treated
with BD Cytofix/Cytoperm and Perm/Wash solutions (BD Bio-
sciences). IFN-γ production was detected by PE-Cy7 anti-mouse
IFN-γ antibody (BD Pharmingen). Samples were run on a FACS
Canto II (Becton-Dickinson, San Jose, USA) and analyzed using
Flow Jo 8.7 software (TreeStar Inc., Ashland, OR, USA) and Sw
Gatelogic (IniVai Technologies, Mentone Victoria 3194,Australia).
STATISTICAL ANALYSES
Statistical analyses were performed via GraphPad Prism, using
the unpaired two-tailed Student’s t -test. n.s.: not significant;
∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001.
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APPENDIX
FIGURE A1 | Doxycycline and IL-18BP combination therapy. Prf1
KO mice were infected with DN-SCP-MCMV and treated with IL-18BP,
DOX, or both. Six days after infection mice were sacrificed and
different parameters were evaluated. (A) White blood cell,
lymphocyte, and platelet counts in peripheral blood, expressed as the
mean±SEM of four mice per group. *p< 0.05; n.s., not significant.
(B) Viral titers in the liver, expressed as the mean±SEM of three
mice per group.
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